Oncology Corporate Profile
Kirax Corporation, formerly known as Tigris Pharmaceuticals, focuses on acquiring, developing and commercializing innovative specialty care therapies with emphasis on oncology, pain, inflammation, acute and supportive care. Building on its core competencies in clinical development, regulatory affairs, safety and commercialization, Kirax licenses or acquires rights to compounds in various stages of clinical development as well as in-market products.
|Brand / Product||Class||Area of Study||Phase||Partnership|
|GFB-204||VEGFR and PDGFR inhibitor||Various cancer types||Preclinical|
|GGTI-2418||peptidomimetic inhibitor of geranylgeranyltransferase I (GGTase I) (synthetic)||Various cancer types||Preclinical|
View additional information on product candidates here »
5/16/2012 03:02 pm
[Zacks] - Investments in the real estate sector are expected to provide excellent protection against inflationary pressures.
4/11/2012 07:02 pm
[Zacks] - For investors looking to park their funds in the real estate sector, mutual funds are the most cheapest and convenient method.